Bookmark and Share
BioAssay: AID 2627

Western Blot Cell-Based Dose Response to Identify Activators of Alpha-Synuclein Translation in H4 Cells

Jack T. Rogers, Massachusetts General Hospital, jtrogers@rics.bwh.harvard.edu, 617-726-8838, Charlestown, MA ..more
_
   
 Tested Compounds
 Tested Compounds
All(1)
 
 
Active(1)
 
 
 Tested Substances
 Tested Substances
All(1)
 
 
Active(1)
 
 
 Related BioAssays
 Related BioAssays
AID: 2627
Data Source: Broad Institute (2023-05_ACTIVATORS_DOSE-TITRATION_MLPCN-DRYPOWDER)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
BioAssay Version:
Deposit Date: 2010-03-21
Hold-until Date: 2010-09-30
Modify Date: 2011-01-12

Data Table ( Complete ):           Active    All
BioActive Compound: 1
Depositor Specified Assays
AIDNameTypeComment
1813MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitorsscreeningPrimary HTS
1829Broad Institute MLPCN Alpha-Synuclein 5'UTR - ActivatorssummaryProject Summary
Description:
Broad Institute MLPCN Alpha-Synuclein 5'UTR Project

Project ID: 2023

Keywords: alpha-synuclein, Parkinson's disease, translation, RNA stem-loop, 5'-untranslated region

Primary Collaborators (and laboratory where this assay was performed):
Jack T. Rogers, Massachusetts General Hospital, jtrogers@rics.bwh.harvard.edu, 617-726-8838, Charlestown, MA

Project Overview:
The goal of this project is to identify novel small molecule probes that increase alpha-synuclein translational expression in dopaminergic neurons by targeting the 5'-untranslated region (5'UTR) stem-loop of alpha-synuclein as a novel probe for alpha-synuclein translational expression. The 5'UTR of alpha-synuclein mRNA can interact with Iron Regulatory Protein-1 (IRP1), which upon interaction causes an increase in alpha-synuclein mRNA translation. Increased levels of alpha-synuclein have been directly linked to Parkinson's disease. Probes that can successfully increase alpha-synuclein expression levels as measured in this luciferase reporter assay will be further tested for specificity in cells lacking the alpha-synuclein 5'UTR stem-loop to confirm that probes are acting through the intended target. Probe selectivity will be tested in cells containing the prion protein 5'UTR mRNA stem-loop and also in cells containing the amyloid precursor protein 5'UTR mRNA stem-loop, both of which are fused to a luciferase reporter.

Assay Overview: In the Western blot orthogonal screen, confirmation of alpha-synuclein translation activators was sought. The Western used H4 neuroblastoma cells that were not transfected. Compound was tested in 3-point dose in an effort to observe a dose-dependent effect.

Expected Outcome: Activators of alpha-synuclein translation should increase alpha-synuclein protein levels without affecting actin levels.
Protocol
Cell Culture and Preparation of Lysates:

1. Human H4 neuroglioblastoma cells were cultured in Dulbeccos modified essential medium (Invitrogen) supplemented with 10% FBS (Invitrogen) and penicillin/streptomycin (Bio-Whittaker, Walkerville, MD). Cells were exposed to increasing concentrations of compound (0, 0.1, 1, 10 micromolar) for 48 hours.

2. Cytoplasmic protein lysates were prepared by homogenizing the cells in midRIPA buffer (25 mM Tris pH 7.4, 1% NP40, 0.5% sodium deoxycholate, 15 mM NaCl, protease inhibitors, RNase inhibitor and 10 mM DTT).

Western Blot:

1. Western blotting for alpha-synuclein was performed using mouse monoclonal anti-alpha-synuclein (BD Transduction Laboratories), and anti-beta-actin (Chemicon).

2. The blots were developed using chemiluminescence (PIERCE) and visualized with a PhosphoImager (BioRad, Hercules, CA), and bands were quantified using QuantityOne software (BioRad).
Comment
Dose Response Data Analysis:
Neutral control condition (DMSO) was included.
Corrected SCNA was calculated as: Density of SNCA at dose / Density of Actin at dose

Percent activation of SNCA expression was calculated as follows:
100 * ((Corrected SNCA at dose/ Corrected SCNA at neutral) - 1)

ECMax was determined to be the dose that supported Maximum Observed Activity.

PUBCHEM_ACTIVITY_SCORE
Inactive compounds = 0
Active compounds = -10 * Log(ECMax)

PUBCHEM_ACTIVITY_OUTCOME
Activity_Outcome = 1 (inactive)
Dose Dependent Activity is not observed.

Activity_Outcome = 2 (active)
Dose Dependent Activity is observed.
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1ECMax Qualifier'>', '=', or '<'String
2ECMax*the concentration whereupon perceived activity reaches the maximum value observedFloatμM
3Max. Activitythe maximum activity value observedFloat%
4Activity at 10uM (10μM**)The measured activity at the specified concentrationFloat%
5Activity at 1uM (1μM**)The measured activity at the specified concentrationFloat%
6Activity at 0.1uM (0.1μM**)The measured activity at the specified concentrationFloat%
7Activity at 0uM (0μM**)The measured activity at the specified concentrationFloat%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1-R21-NS-059434-01

Data Table (Concise)
PageFrom: